SCHEMBL19203256

SCHEMBL19203256

CC(=O)c1ccc(Br)cc1CC(C)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.44
ALOX12 P18054 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.42
MAOA P21397 4/20 0.39
MAOB P27338 3/20 0.39
HSD17B1 P14061 1/20 0.38
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HPGD P15428 2/20 0.36
DGAT1 O75907 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CES2 O00748 1/20 0.34
GALR3 O60755 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CASP1 P29466 1/20 0.34
CYP2C19 P33261 1/20 0.34
CUL4A Q13619 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10141739 0.82 PTGDR2 (0.46) ALOX15ALOX12PTGDR2MAOAMAOB
SCHEMBL6513432 0.80 HSD17B1 (0.56) ALOX15PTGDR2MAOAMAOBHSD17B1
SCHEMBL15820026 0.80 USP2 (0.47) L3MBTL1HPGDALDH1A1
SCHEMBL15192041 0.80 USP2 (0.47) L3MBTL1HPGDALDH1A1
SCHEMBL15197102 0.79 PTGDR2 (0.47) ALOX15PTGDR2MAOAMAOBHSD17B1
SCHEMBL19203255 0.77 PTGDR2 (0.45) ALOX15ALOX12PTGDR2MAOAMAOB
SCHEMBL15197077 0.76 PTGDR2 (0.44) ALOX15PTGDR2MAOAMAOBHSD17B1
SCHEMBL28401340 0.75 GABRA1 (0.47) ALOX15ALOX12POLBHPGDKDM4E
SCHEMBL15197075 0.75 MAOA (0.47) PTGDR2MAOAMAOBHSD17B1HPGD
SCHEMBL4167084 0.75 MAPT (0.47) POLBL3MBTL1KDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170217920-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217920-A1 ANTIDIABETIC BICYCLIC COMPOUNDS GPR119, GPR65, GLP1R ALOX15 1296/4885ALOX12 1484/4885PTGDR2 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.